کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5524315 1546247 2016 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoi
ترجمه فارسی عنوان
پیوند سلولی هموگلوبین هماتوپوئیدی برای انتقال ترشح لوسمی پیش از نئوپلاسم های میلوپرولیفراتیومی منفی کروموزوم فیلادلفیا: یک بررسی سراسری توسط گروه کارآزمایی لوسمی میلوئید حاد بزرگسالان انجمن ژاپنی هماتوپوی
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
چکیده انگلیسی


- One-third of patients with leukemic transformation from Philadelphia chromosome-negative myeloproliferative neoplasms survived for long-term
- The largest number of umbilical cord blood transplantations for leukemic transformation from Philadelphia chromosome-negative myeloproliferative neoplasms was included in this study
- Umbilical cord blood transplantation provided 25% of 2-year overall survival for patients not in remission

To clarify the outcome of allogeneic hematopoietic cell transplantation (HCT) for leukemic transformation (LT) preceded by Philadelphia chromosome-negative (Ph-neg) myeloproliferative neoplasms (MPNs), we conducted a retrospective study using the national registry database of the Japan Society for Hematopoietic Cell Transplantation. From 2000 to 2013, 39 patients underwent their first allogeneic HCT with related bone marrow or peripheral blood stem cells (n = 8), unrelated bone marrow (n = 15), and unrelated umbilical cord blood (n = 16). The median patient age was 57 years. The underlying Ph-neg MPNs included 21 cases of essential thrombocythemia, 11 cases of primary myelofibrosis, and 7 cases of polycythemia vera. The median interval between the diagnosis of LT and transplantation was 134 days. Thirty-two cases (82%) were not in remission at the time of transplantation. The 2-year overall survival rate was 29.2% (95% confidence interval [CI], 15.5% to 44.3%). The median follow-up of the surviving patients was 1989.5 days (range, 285 to 3270). The cumulative incidences of relapse and nonrelapse mortality at 2 years were 34.4% (95% CI, 19.6% to 49.8%) and 34.2% (95% CI, 19.6% to 49.4%), respectively. The study results suggested that allogeneic HCT provides long-term survival in approximately one-third of patients with LT preceded by Ph-neg MPNs.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biology of Blood and Marrow Transplantation - Volume 22, Issue 12, December 2016, Pages 2208-2213
نویسندگان
, , , , , , , , , , ,